Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TXA-127 by Constant Therapeutics for Ischemic Stroke: Likelihood of Approval
TXA-127 is under clinical development by Constant Therapeutics and currently in Phase II for Ischemic Stroke. According to GlobalData, Phase...
Data Insights
TXA-127 by Constant Therapeutics for Dilated Cardiomyopathy: Likelihood of Approval
TXA-127 is under clinical development by Constant Therapeutics and currently in Phase II for Dilated Cardiomyopathy. According to GlobalData, Phase...